|
|
|
|
|
| Instant Update: Fri 3 Sept
|
|
PBS savings double counted - Coalition got it wrong says Treasury; More pressure on Reductil - NEJM highly critical; Spending in chemists surges - But doctor visits drop; Arm's length review for Avexa - Seeks clear picture of portfolio value » full report |
|
| Baxter rocked by $4.9m ACCC fine
|
|
After an eight year battle that went as far as the High Court, Baxter has been fined $4.9 million over contracts with state governments for the supply of dialysis products that were found to have breached the Trade Practices Act » full report |
|
| MoU deadline looking shaky
|
|
With post-election political uncertainty dragging into its second week, Medicines Australia has conceded that the longer it takes to form a new government, the less likely it is that the Bill containing the MoU will be enacted by October 1 » full report |
|
| Consumers want promotion law
|
|
As the Trimmer committee on promotion of therapeutic goods prepares to meet for the second time this week, consumers are telling its inquiry that only legislation will ensure public health priorities are upheld » full report |
|
| Aussie pharmacy still a good gig
|
|
Australian pharmacists tend to be significantly less concerned about reimbursement, generic drug and political uncertainty issues than their counterparts in other countries a new survey has found » full report |
|
| Judges boost injunction numbers
|
|
The 2007 introduction of the automatic 12.5% PBS price reduction when a generic drug enters the market has led to a significant increase in the number of injunctions granted with judges showing sympathy for innovators.
» full report |
|
| Soliris remains distant from funding
|
|
A decision on whether an expensive treatment for a rare blood disorder meets the criteria for inclusion on the Life Saving Drugs Program (LSDP) is likely to be further delayed by the election stalemate. (Includes full PBAC outcomes.) » full report |
|
| Abilify patent amendment costly
|
|
An attempt to amend its patent on schizophrenia drug Abilify (aripiprazole) - sold in Australia by Bristol-Myers Squibb - while revocation proceedings are on foot has resulted in a costs order against originator Otsuka Pharmaceutical and in favour of generics maker Apotex » full report |
|
|
|
|
|
|
|
|
| © 2007 Lush Media | Privacy Statement | Subscribe to Pharma in Focus | Design: Jolly Good Design
|
